New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term...

{
  "signal_id": "ef844886-fa9b-c48d-5cda-ab191c4b99c4",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-23T13:46:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/new-model-based-analysis-further-supports-the-potential-of-tecvayli-teclistamab-cqyv-plus-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-to-redefine-long-term-survival-expectations-in-early-line-relapsedrefractory-multi-302887782.html",
    "title": "New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma",
    "excerpt": "RARITAN, N.J. , Sept. 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI ® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy. 1,2 Using a relative survival mixture cure model (MCM) and actual progression-free survival (PFS) and overall survival (OS) data from the trial, statistical modeling estimated that ~87% of patients treated with TECVAYLI ® plus DARZALEX FASPRO ® (Tec-Dara) may experience a mortality risk and projected life expectancy similar to an age-matched general population. 1 Modeling further predicted that median overall survival with Tec-Dara would be nearly four-fold longer than with the standard of care (SOC) comparator in the study, dexamethasone with pomalidomide or bortezomib (DPd/DVd). These data help to illustrate to what extent treatment with TECVAYLI ® plus DARZALEX FASPRO ® as early as second line may reshape survival expectations in multiple myeloma. 1 In the MajesTEC-3 study, TECVAYLI ® plus DARZALEX FASPRO ® significantly improved overall survival versus standard of care (SOC), with an estimated 83% of patients alive at 3 years. 3 A post hoc...",
    "product": "TECVAYLI plus DARZALEX FASPRO",
    "summary": "Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study for its combination therapy of TECVAYLI® and DARZALEX FASPRO® for relapsed or refractory multiple myeloma, showing sustained disease control and survival.",
    "location": "Raritan, NJ, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA2964942&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "TECVAYLI plus DARZALEX FASPRO",
      "full_text": "TECVAYLI ® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-23T13:46:00Z",
    "location_data": [
      {
        "city": "Raritan",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-23",
    "article_sentence": "Johnson & Johnson (NYSE: JNJ ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI ® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy."
  }
}

curl https://signals.autobound.ai/v1/signals/ef844886-fa9b-c48d-5cda-ab191c4b99c4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'